Efficacy and Safety Study of Benralizumab for Patients With Severe Nasal Polyposis

Condition:   Nasal Polyposis Interventions:   Biological: Benralizumab 30 mg SC + Mometasone Furoate;   Biological: Matching placebo SC + Mometasone Furoate Sponsor:   AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials